Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > REGULATORY
REGULATORY
- Japan Aims to Make Pfizer COVID-19 Pills Available Next Month: PM
January 18, 2022
- MHLW Panel Positive for OTC Switch for 4 Drugs Including Xyzal, Cautious on Rozerem
January 18, 2022
- Difolta Label Updated to Alleviate ADRs by Using Folinate
January 18, 2022
- Takecab Faces 2nd “Huge-Seller” Price Slash, All GLP-1 Injectables to Get Cut Too on Market Expansion
January 18, 2022
- Bayer’s CKD Drug Finerenone Up for PAFSC Review on Jan. 28
January 17, 2022
- FY2022 Medical Fee Reform Plans OK’ed by Chuikyo, No Mention of Formulary
January 17, 2022
- MHLW Presents Preventive Steps after SaMD Deferred Coverage Case: Chuikyo
January 17, 2022
- Japan Cuts Review Fees for Fertility Treatments by Half
January 14, 2022
- Pfizer’s Comirnaty Up for PAFSC Review for Ages 5-11 on Jan. 20; Actemra to Add COVID-19 Use
January 14, 2022
- MHLW to Promote Use of Generics, Biosimilars through FY2022 Medical Fee Schedule Revision: Chuikyo
January 13, 2022
- AMED to Set Up SCARDA in March to Spearhead Vaccine Development: President
January 12, 2022
- Govt to Move Up Booster Schedule for Workplace Program Too: Minister
January 12, 2022
- PM Kishida Vows to Hasten COVID-19 Vaccinations for under Age 12
January 12, 2022
- MHLW to Revise Laws to Allow Doctors to Issue Electronic Scripts
January 11, 2022
- MHLW Eyes Evaluation Indices and Guidelines to Fuel Rollout of SaMD and Cell & Gene Therapies: Official
January 11, 2022
- Govt to Submit PMD Law Amendment Bill in Ordinary Diet Session to Introduce Emergency Approval
January 7, 2022
- Rewarding Innovation Was the Primary Goal in 2022 Reform Debate: MHLW Official
January 7, 2022
- MHLW to Reshuffle Organization by Summer to Further Support Drug Development; Economic Affairs Division to Be Renamed
January 7, 2022
- MHLW’s COVID-19 Guide Adds MSD’s Molnupiravir
January 6, 2022
- Japan’s Drug Production Down 1.9% to 9.3 Trillion Yen in 2020: MHLW
January 6, 2022
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…